What is it about?
An analysis of the number of drugs approvals from 2011 to the first four months of 2018. This is followed by a review of the FDA's initiative to optimize the way it review drugs. The FDA released new guidance fo the development of drugs to treat five neurological diseases. The new guidance fro the development of drugs to treat Alzheimer's disease and acute migraine headaches are viewed as examples of the updated recommendations from the FDA.
Featured Image
Why is it important?
The editorial provides a review of the process used to review investigational drugs.
Read the Original
This page is a summary of: FDA Guidance and New Drug Approvals, Hospital Pharmacy, May 2018, SAGE Publications,
DOI: 10.1177/0018578718779355.
You can read the full text:
Contributors
The following have contributed to this page
